Prevalence of thyroid dysfunction in older Chinese patients with type 2 diabetes-A multicenter cross-sectional observational study across China.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 30 10 2018
accepted: 15 04 2019
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 23 2 2020
Statut: epublish

Résumé

Type 2 diabetes [T2D] and thyroid dysfunction [TD] often co-occur, have overlapping pathologies, and their risk increases with age. Since 1995, universal salt iodization has been implemented in China to prevent disorders caused by iodine deficiency. However, after two decades of implementation of universal salt iodization, the prevalence of TD in elderly Chinese patients with T2D is not well described and may have been underestimated. We conducted a questionnaire-based survey across 24 endocrinology centers in China between December 2015 and July 2016. Demographic and clinical data from 1677 patients with T2D were obtained and analyzed to examine the prevalence of TD along with T2D in these patients. We assessed TD prevalence according to the four TD subtypes [subclinical hypothyroidism, clinical hypothyroidism, subclinical hyperthyroidism, and clinical hyperthyroidism], TD history, gender, and age. The diagnosis rates were calculated for TD and also for the TD subtype. The number of patients reaching treatment goals for T2D [hemoglobin A1c <7%] and TD [normal free thyroxine and thyroid-stimulating hormone [TSH]] and the incidences of complications and comorbidities were recorded. Among the enrolled patients with T2D [N = 1677], TD was diagnosed in 23.79% [399/1677] out of which 61% (245/399) were previously diagnosed and 38.59% (154/399) were newly diagnosed cases. Subclinical hypothyroidism, clinical hypothyroidism, subclinical hyperthyroidism, and clinical hyperthyroidism were reported in 4.89%, 9.3%, 1.13%, and 3.16% of the total population, respectively. Among patients previously diagnosed with TD, the incidence in women [166/795; 20.88%] was higher than in men [79/882; 8.96%]. The treatment goals for TD and T2D were attained in 39.6% [97/245] and 34.41% [577/1677] of the cases, respectively. Diabetic complications and comorbidities were reported in 99.7% of patients, with peripheral neuropathy being the most common [43.46%] followed by cataract [24.73%]. We had found that the incidences of dyslipidemia, elevated LDL levels, and osteoporosis were significantly higher in patients with TD than those without TD. TD is underdiagnosed in elderly Chinese patients with T2D.

Identifiants

pubmed: 31048873
doi: 10.1371/journal.pone.0216151
pii: PONE-D-18-30075
pmc: PMC6497275
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0216151

Déclaration de conflit d'intérêts

The authors declare that no competing interests exist. Linong Ji received study funding from Merck Serono China Co. Ltd., an affiliate of Merck KGaA, Darmstadt, Germany. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Am J Physiol. 1985 May;248(5 Pt 1):E593-601
pubmed: 3887944
J Thyroid Res. 2013;2013:481287
pubmed: 24106641
Arch Intern Med. 1975 Nov;135(11):1477-80
pubmed: 1190932
N Engl J Med. 2006 Jun 29;354(26):2783-93
pubmed: 16807415
Endocr Pract. 2016 Feb;22(2):262-70
pubmed: 26848631
Diabet Med. 1995 Jul;12(7):622-7
pubmed: 7554786
BMC Med. 2016 Sep 30;14(1):150
pubmed: 27686165
Clin Endocrinol (Oxf). 1977 Dec;7(6):481-93
pubmed: 598014
J Clin Endocrinol Metab. 2007 Jan;92(1):203-7
pubmed: 17032713
J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
pubmed: 11836274
Thyroid. 2016 Aug;26(8):1125-30
pubmed: 27370068
Medicine (Baltimore). 2017 Jun;96(25):e7279
pubmed: 28640139
Ter Arkh. 2014;86(8):119-23
pubmed: 25306758
Exp Ther Med. 2015 Jan;9(1):3-10
pubmed: 25452768
J Clin Endocrinol Metab. 1993 Jan;76(1):79-84
pubmed: 8421108
Diabetes Care. 2010 May;33(5):1018-20
pubmed: 20150298
Diabet Med. 2007 Dec;24(12):1336-44
pubmed: 17941864
Nat Clin Pract Endocrinol Metab. 2007 Sep;3(9):632-40
pubmed: 17710084
Saudi Med J. 2004 Aug;25(8):1046-50
pubmed: 15322596
JAMA. 2017 Jun 27;317(24):2515-2523
pubmed: 28655017
Diabet Med. 2012 Dec;29(12):1510-4
pubmed: 22507223
Int J Clin Pract. 2010 Jul;64(8):1130-9
pubmed: 20642711
Am Fam Physician. 2002 Apr 1;65(7):1467
pubmed: 11996428
Arch Pathol Lab Med. 1996 Oct;120(10):929-43
pubmed: 12049072
PLoS One. 2018 Jun 14;13(6):e0199006
pubmed: 29902222
Endocr J. 2011;58(12):1065-70
pubmed: 21931224
Acta Diabetol. 2006 May;43(1):14-8
pubmed: 16710644
J Pharmacol Pharmacother. 2012 Apr;3(2):156-60
pubmed: 22629091
Clin Lab. 2014;60(9):1551-9
pubmed: 25291952
J Diabetes Res. 2013;2013:390534
pubmed: 23671867
Diabetol Metab Syndr. 2013 Oct 09;5(1):58
pubmed: 24499529
J Investig Med. 2012 Jan;60(1):23-8
pubmed: 21997314
Exp Clin Endocrinol Diabetes. 2011 Apr;119(4):201-7
pubmed: 21465427
J Thyroid Res. 2011;2011:439463
pubmed: 21785689
J Gerontol. 1991 Jan;46(1):B39-44
pubmed: 1986034
J Family Med Prim Care. 2020 Aug 25;9(8):4277-4281
pubmed: 33110845
Med Sci Monit. 2017 Jun 04;23:2715-2720
pubmed: 28578377
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067

Auteurs

Yu Zhu (Y)

Peking University People's Hospital, Beijing, China.

Fengmei Xu (F)

General Hospital of Hebi Coal Industry [Group] Co., Ltd., Hebi, China.

Jie Shen (J)

The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.

Youshuo Liu (Y)

The Second Xiangya Hospital of Central South University, Changsha, China.

Changhua Bi (C)

CNPC Central Hospital, Hebei, China.

Jing Liu (J)

Gansu Provincial Hospital, Lanzhou, China.

Yufeng Li (Y)

Beijing Pinggu Hospital, Beijing, China.

Xueqin Wang (X)

Beijing Huairou Hospital of University of Chinese Academy Sciences, Beijing, China.

Zhengnan Gao (Z)

Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, China.

Linlang Liang (L)

The General Hospital of Shenyang Military Region, Shenyang, China.

Yanyan Chen (Y)

Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China.

Weiping Sun (W)

The First People's Hospital of Xiangtan City, Xiangtan, China.

Qingbo Guan (Q)

Shandong Provincial Hospital, Shandong, China.

Junqing Zhang (J)

Peking University First Hospital, Beijing, China.

Zuojie Luo (Z)

The First Affiliated Hospital of Guangxi Medical University, Guangxi, China.

Lixin Guo (L)

Beijing Hospital, Beijing, China.

Xiaopin Cai (X)

China-Japan Friendship Hospital, Beijing, China.

Ling Li (L)

Shengjing Hospital of China Medical University, Shenyang, China.

Lingling Xiu (L)

First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Li Yan (L)

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.

Chunlin Li (C)

The General Hospital of the People's Liberation Army [301 Hospital], Beijing, China.

Xiaoyun Shi (X)

The General Hospital of Chinese People's Armed Police Forces, Beijing, China.

Mei Zhu (M)

General Hospital, Tianjin Medical University, Tianjin, China.

Jian Kuang (J)

Guangdong General Hospital, Guangzhou, China.

Guangwei Li (G)

Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China.

Linong Ji (L)

Peking University People's Hospital, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH